ModernMedicine Resource Center More Topics

DME Resource Center

Steroids may be preferable to anti-VEGF for DME in certain casesTwo-year study results highlight some advantages of steroid treatment for DME.
Investigational pipeline for DME looks promisingPharmacotherapy research for diabetic macular edema is looking at targets other than VEGF inhibition to develop treatments that can be used as standalone intervention or may be complementary to current options.
Anti-VEGF patterns of use for DME may vary in clinical practiceThough anti-vascular endothelial growth factor therapy for diabetic macular edema showed impressive results in trials, clinicians have reported less success on their own.
PKal May Join VEGF as DME pathwayA protein called PKal (plasma kallikrein) and its associated molecules are key players in an inflammatory molecular pathway involved in diabetic macular edema, according to a study published in Diabetes.
Prior vitrectomy does not affect DME therapy with ranibizumab, laserAnalysis of eyes with and without prior vitrectomy from DRCR Protocol I showed similar results when treated with ranibizumab with prompt or deferred laser.
Intravitreal sirolimus shows promise for noninfectious posterior segment uveitisSAKURA is a 24-month phase III study investigating the efficacy and safety of intravitreal sirolimus for treatment of noninfectious posterior segment uveitis. Data were reported from the primary endpoint visit at 5 months.
FDA approves Iluvien for long-term treatment of DME; Alimera reactsThe FDA has approved Alimera Sciences’ fluocinolone acetonide intravitreal implant (Iluvien) for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in IOP.
Iluvien for chronic DME approved for marketing in Denmark, NorwayThe Danish Health and Medicines Authority, along with the Norwegian Medicines Evaluation Board, have granted marketing authorization to Alimera Sciences’ Iluvien for the treatment of vision impairment associated with chronic diabetic macular edema (DME) in their respective countries.
RIDE, RISE phase III results favorable for DME treatment
RIDE, RISE phase III results favorable for DME treatmentThe open-label extension RIDE and RISE phase III studies of ranibizumab (Lucentis, Genentech) indicated that the beneficial results of the drug for treating diabetic macular edema were maintained over the long-term with less than monthly follow-up or injection treatment.
ThromboGenics to expand VMA, DME researchThromboGenics has taken steps to expand its research of treatments for vitreomacular adhesion (VMA) and diabetic macular edema (DME).